BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, November 11, 2025
Home » Topics » Clinical

Clinical
Clinical RSS Feed RSS

On the Climb in IgAN; Vera well done?

Oct. 31, 2025
By Randy Osborne
No Comments
Vera Therapeutics Inc.’s atacicept gained still more airtime at the Cantor Fitgerald health care conference held Sept. 4, and some on Wall Street believe the appetite for the BAFF and APRIL dual inhibitor could bode well for others in the same mechanistic space.
Read More

Vesper's oral frontotemporal dementia drug positive in phase Ib/II

Oct. 31, 2025
By Nuala Moran
No Comments
Neurodegeneration specialist Vesper Bio ApS has announced positive results from the phase Ib/II trial of its oral sortilin inhibitor VES-001 in frontotemporal dementia. The small study involved six participants who had not progressed to symptomatic disease but were carriers of mutations in the GRN gene that codes for progranulin, a growth factor that is essential for neuronal health.
Read More
Tape measure wrapped around scale

Wave, Ibio activin E action in obesity early but solid

Oct. 31, 2025
By Randy Osborne
No Comments
The activin E mechanism of action in obesity is having something of an early stage heyday with such players as Wave Life Sciences Ltd. and Ibio Inc. talking up data that have perked the ears of Wall Street.
Read More
Smartphone displaying Stethophone app

Sparrow feathers nest with C$10M for Stethophone expansion

Oct. 30, 2025
By Annette Boyle
Sparrow Acoustics Inc., dba Sparrow Bioacoustics Inc., closed a C$10 million (US$7.15 million) financing round to support continued adoption of its U.S. FDA-cleared Stethophone platform, which allows bioacoustics detection of structural and rhythmic heart anomalies directly through a smartphone. Sparrow is a Software as a Medical Device and the first medically cleared product that uses smartphones to capture and decipher cardiac sounds.
Read More
Cross-section of brain

Lumosa’s stroke drug meets phase IIb endpoints in China

Oct. 30, 2025
By Tamra Sami
No Comments
Lumosa Therapeutics Co. Ltd.’s intravenous odatroltide (LT-3001) met the primary endpoints in a phase IIb trial in China in patients with acute ischemic stroke, paving the way for a pivotal phase III study.
Read More
3D heart in chest
TCT 2025

Data suggest more than 10M people in the US have bad heart valves

Oct. 29, 2025
By Mark McCarty
The prevalence of valvular heart disease in the U.S. is tough to peg with any great precision, but an extrapolation of data from a new study would put the number at roughly 10.6 million people, a staggering number when the clinical and fiscal implications are considered.
Read More
Test tubes with blood samples

Blood test breakthrough could transform Alzheimer’s diagnosis

Oct. 29, 2025
By Tamra Sami
Australian scientists have developed a simpler, less invasive way to detect Alzheimer’s disease that could make it easier for patients to access emerging disease-modifying therapies. Researchers from Australia’s Commonwealth Scientific and Industrial Research Organisation have identified blood-based biomarker tests capable of confirming amyloid plaque in the brain with accuracy comparable to the current gold standards using positron emission tomography scans and lumbar punctures.
Read More
Illustration of nerve cells

Amen at AANEM: Kyverna makes good on MG phase II promise

Oct. 29, 2025
By Randy Osborne
No Comments
Shooting for further proof of durable, drug-free, disease-free remission with a single dose of KYV-101 in generalized myasthenia gravis, Kyverna Therapeutics Inc. plans to start phase III work by the end of this year. The Emeryville, Calif.-based firm rolled out positive interim results from the phase II portion of the registrational Kysa-6 clinical trial testing the drug, a fully human, autologous, CD19 CAR T-cell therapy with CD28 costimulation.
Read More
3D illustration of thyroid in human body with parathyroid glands highlighted

Bridgebio wows again, this time in genetic hypoparathyroidism

Oct. 29, 2025
By Jennifer Boggs
No Comments
Only two days after Bridgebio Pharma Inc. impressed investors with data from BBP-418 in limb-girdle muscular dystrophy type 2I/R9, the company was back at it again, this time reporting positive top-line results from its global phase III study of encaleret in autosomal dominant hypocalcemia type 1, a genetic form of hypoparathyroidism.
Read More
Edwards Lifesciences Sapien M3

Data from Partner 3 low-risk affirms TAVR even with SAVR

Oct. 28, 2025
By Mark McCarty
Stakeholders of all stripes have wondered whether transcatheter aortic valve replacement devices could match their surgically implanted cousins for device durability, but seven-year data from the Partner 3 trial seems to suggest that patients, physicians, payers and regulators need not fret as the topline numbers showed no statistically significant difference for outcomes such as mortality and morbidity.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 420 421 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Nov. 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Nov. 10, 2025.
  • Illustration of women's reproductive organs

    Biomarker panel of three serum microRNAs predicts cervical cancer prognosis

    BioWorld Science
    MicroRNAs (miRNAs) play key roles in cancer development by regulating genes involved in cell growth, differentiation, invasion, metastasis and angiogenesis....
  • Illustration of magnifying glass inspecting brain

    Anchoring, and bootstrapping, psychiatry into the precision medicine era

    BioWorld Science
    Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...
  • Art concept for medical research

    With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

    BioWorld
    Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing